HLB Co., Ltd. With a strong commitment to open innovation, HLB has built a diverse pipeline of novel anticancer compounds through its global network. At the core of HLB's mission is the goal to bring more than 5 anticancer drugs to market by 2025, starting with the best-in-class targeted therapy, 'Rivoceranib,' and the next-generation immunotherapy vaccine platform, 'UNITE,' targeting cancer and allergies.

HLB's corporate philosophy is rooted in warm capitalism, mature corporate citizenship, and practical business ethics. Since its establishment in 1975, HLB has undergone remarkable growth, evolving from a small shipbuilding company producing lifeboats and fiberglass pipes to a global pharmaceutical and biotech powerhouse. HLB's fearless spirit of overcoming challenges and pursuing dreams is reflected in its strong corporate ethics and entrepreneur spirit.

Join HLB on this exciting journey towards its 50th anniversary and be a part of realizing a better future for mankind